CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials.
A 3-D illustration of CAR-T cell therapy in breast cancer.Adobe
By Allison DeAngelis
May 14, 2026
Biotech Startups and Venture Capital Reporter
Allison DeAngelis
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
After embarking on a trial of CAR T-cell therapy, actor Sam Neill announced he is cancer-free. Researchers are enthusiastic the…
CAR-T è estremamente costoso, circa 300.000-350.000 euro per paziente, per varie ragioni
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo…
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
